Medical insurance reimbursement ratio for Obinutuzumab

Obinutuzumab is a CD20-directed cytolytic antibody. Current clinical studies indicate that Obinutuzumab can be used in combination with chlorambucil to treat previously untreated chronic lymphocytic leukemia. Otuzumab can also be combined with bendamustine, followed by otuzumab monotherapy, in patients with follicular lymphoma or who are refractory to rituximab-containing regimens. Indicated for the treatment of adults with previously untreated stage II large follicular, stage III, or IV follicular lymphoma in combination with chemotherapy followed by otuzumabmonotherapy in patients who achieve at least a partial response. Otuzumab or any excipient, including serum, is contraindicated in patients with known allergic reactions to diseases with previous use of otuzumab.

The original drug of Otuzumab has been launched in China and has entered the scope of medical insurance, but it is only reimbursed for patients who meet the indications. Specifications The price of 1000mg (40ml)*1 bottle may be more than 9,000 yuan. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. For specific information, please consult the local medical insurance bureau or hospital. The price of the Turkish version of Otuzumab Specifications1000mg/40ml per box listed overseas may be around RMB 10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drugs sold domestically and abroad are basically the same. There is currently no generic version of Otuzumab produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.